Allergic rhinitis (AR) is an IgE-mediated inflammation which causes olfactory dysfunction. Antihistamines have been widely used to treat AR while few studies have investigated the effect of antihistamines on improving the sense of smell. In addition, the underlying mechanisms are not well elucidated. We established the ovalbumin (OVA)-induced allergic rhinitis rat model and administrated desloratadine to AR rats. The AR symptoms, serum level of OVA-specific IgE and IL-17, and expression of IL-4, IL-5 and IL-13 in nasal mucosa were measured. The olfactory dysfunction was monitored by buried food test and the expression of GluR1 was measured. Desloratadine treatment alleviated AR symptoms, decreased serum level of OVA-specific IgE and IL-17 in AR rats. Desloratadine decreased IL-4, IL-5, and IL-13 expression in nasal mucosa of AR rats. Desloratadine ameliorated olfactory dysfunction in AR rats and decreased GluR1 expression in AR rats. Desloratadine treatment alleviated AR symptoms and ameliorated olfactory dysfunction in AR rats. The expression of AMPA receptor subunit GluR1 in olfactory bulb was associated with olfactory disorder.

中文翻译：

---

地氯雷他定改善过敏性鼻炎大鼠嗅觉障碍并抑制AMPA受体GluA1表达。

变应性鼻炎（AR）是IgE介导的炎症，会引起嗅觉功能障碍。抗组胺药已被广泛用于治疗AR，而很少有研究研究抗组胺药对改善嗅觉的作用。另外，还没有很好地阐明潜在的机制。我们建立了卵白蛋白（OVA）诱导的变应性鼻炎大鼠模型，并向AR大鼠给药去氯雷他定。测量了鼻粘膜的AR症状，OVA特异性IgE和IL-17的血清水平以及IL-4，IL-5和IL-13的表达。通过掩埋食品测试监测嗅觉功能障碍，并测量GluR1的表达。地氯雷他定治疗可减轻AR大鼠的AR症状，降低其OVA特异性IgE和IL-17的血清水平。去氯雷他定可降低AR大鼠鼻黏膜中IL-4，IL-5和IL-13的表达。地氯雷他定改善了AR大鼠的嗅觉功能障碍，并降低了AR大鼠的GluR1表达。地氯雷他定治疗可减轻AR大鼠的AR症状并改善其嗅觉功能障碍。AMPA受体亚基GluR1在嗅球中的表达与嗅觉障碍有关。